Martin Zoche

Dr. Martin Zoche


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
Albrecht  StenzingerAlbrecht Stenzinger
Albrecht Stenzinger
VEVolker Endris
Volker Endris
JBJan Budczies
Jan Budczies
SMSabine Merkelbach-Bruse
Sabine Merkelbach-Bruse
DKDaniel Kazdal
Daniel Kazdal
MDManfred Dietel
Manfred Dietel

15 April 1998 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
DWDietmar Weitz
Dietmar Weitz
MZMartin Zoche
Martin Zoche
FMFrank Müller
Frank Müller
MBMichael Beyermann
Michael Beyermann
HKHeinz G. Körschen
Heinz G. Körschen
Karl-Wilhelm KochKarl-Wilhelm Koch
Karl-Wilhelm Koch
Calmodulin (CaM) controls the activity of the rod cGMP‐gated ion channel by decreasing the apparent cGMP affinity. We have examined the mechanism of this modulation using electrophysiological and biochemical techniques. Heteromeric channels, consisting of α‐ and β‐subunits, display a high CaM sensitivity (EC50 ⩽5 nM) similar to the native channel. Using surface plasmon resonance spectroscopy, we identified two unconventional CaM‐binding sites (CaM1 and CaM2), one in each of the N‐ and the C‐terminal regions of the β‐subunit. Ca2+ co‐operatively stimulates binding of CaM to these sites exactly within the range of [Ca2+] occurring during a light response. Deletion of the N‐terminal CaM1 site results in channels that are no longer CaM‐sensitive, whereas deletion of CaM2 has only minor effects. We discuss different models to explain the high‐affinity binding of CaM.

24 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHStefanie Hiltbrunner
Stefanie Hiltbrunner
LCLena Cords
Lena Cords
SKSabrina Kasser
Sabrina Kasser
SFSandra N. Freiberger
Sandra N. Freiberger
SKSusanne Kreutzer
Susanne Kreutzer
ACAlessandra Curioni-Fontecedro
Alessandra Curioni-Fontecedro
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell lung cancer (NSCLC), however, some of the patients develop resistance following initial response. Here, we analyze the immune phenotype of matching tumor samples from a cohort of NSCLC patients showing good initial response to immune checkpoint inhibitors, followed by acquired resistance at later time points. By using imaging mass cytometry and whole exome and RNA sequencing, we detect two patterns of resistance¨: One group of patients is characterized by reduced numbers of tumor-infiltrating CD8+ T cells and reduced expression of PD-L1 after development of resistance, whereas the other group shows high CD8+ T cell infiltration and high expression of PD-L1 in addition to markedly elevated expression of other immune-inhibitory molecules. In two cases, we detect downregulation of type I and II IFN pathways following progression to resistance, which could lead to an impaired anti-tumor immune response. This study thus captures the development of immune checkpoint inhibitor resistance as it progresses and deepens our mechanistic understanding of immunotherapy response in NSCLC.

13 December 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RKRaphael Oliver Koliopanos
Raphael Oliver Koliopanos
ATAlexandre Thiéry
Alexandre Thiéry
DADomingo Aguilera-Garcia
Domingo Aguilera-Garcia
MZMartin Zoche
Martin Zoche
HMHolger Moch
Holger Moch
AZAndreas Ziegler
Andreas Ziegler
Rapid advances in high-throughput DNA sequencing technologies have enabled the conduct of whole genome sequencing (WGS) studies, and several bioinformatics pipelines have become available. The aim of this study was the comparison of 6 WGS data pre-processing pipelines, involving two mapping and alignment approaches (GATK utilizing BWA-MEM2 2.2.1, and DRAGEN 3.8.4) and three variant calling pipelines (GATK 4.2.4.1, DRAGEN 3.8.4 and DeepVariant 1.1.0). We sequenced one genome in a bottle (GIAB) sample 70 times in different runs, and one GIAB trio in triplicate. The truth set of the GIABs was used for comparison, and performance was assessed by computation time, F1 score, precision, and recall. In the mapping and alignment step, the DRAGEN pipeline was faster than the GATK with BWA-MEM2 pipeline. DRAGEN showed systematically higher F1 score, precision, and recall values than GATK for single nucleotide variations (SNVs) and Indels in simple-to-map, complex-to-map, coding and non-coding regions. In the variant calling step, DRAGEN was fastest. In terms of accuracy, DRAGEN and DeepVariant performed similarly and both superior to GATK, with slight advantages for DRAGEN for Indels and for DeepVariant for SNVs. The DRAGEN pipeline showed the lowest Mendelian inheritance error fraction for the GIAB trios. Mapping and alignment played a key role in variant calling of WGS, with the DRAGEN outperforming GATK.

1 December 2019 in JCO Precision Oncology
Verified
Journal Article
Open access
JRJan H. Rüschoff
Jan H. Rüschoff
EGElise Gradhand
Elise Gradhand
Abdullah KahramanAbdullah Kahraman
Abdullah Kahraman
HRHelen Rees
Helen Rees
JFJane L. Ferguson
Jane L. Ferguson
BVBart Vrugt
Bart Vrugt

1 January 1996 in Biochemistry
Verified
Journal Article
Closed access
MZMartin Zoche
Martin Zoche
MBMichael Bienert
Michael Bienert
MBMichael Beyermann
Michael Beyermann
Karl-Wilhelm KochKarl-Wilhelm Koch
Karl-Wilhelm Koch